Zolpidem Use Linked to Motor Vehicle Collisions in Elderly

This article originally appeared here.
Share this content:
Zolpidem Use Linked to Motor Vehicle Collisions in Elderly
Zolpidem Use Linked to Motor Vehicle Collisions in Elderly

THURSDAY, Feb. 25, 2016 (HealthDay News) -- Zolpidem users, especially women and individuals aged ≥80 years, have higher rates of motor vehicle collisions (MVCs), according to a study published online in Sleep Medicine.

John N. Booth III, from the University of Alabama at Birmingham, and colleagues examined the correlation between current use of zolpidem-containing medications and MVCs in 2,000 drivers aged ≥70 years. The five-year MVC and at-fault MVC rate ratios (RRs) were estimated for zolpidem users versus nonusers.

The researchers found that after adjustment, there was attenuation of the RR of MVCs comparing zolpidem users versus nonusers (unadjusted: 1.46; 95 percent confidence interval [CI], 1.02 to 2.08 versus adjusted: 1.38; 95 percent CI, 0.97 to 1.98). The unadjusted and adjusted RRs were 1.65 (95 percent CI, 1.03 to 2.66) and 1.61 (95 percent CI, 1.00 to 2.60), respectively, for women. Among those aged ≥80 years the unadjusted and adjusted RRs were 2.24 (95 percent CI, 1.19 to 4.57) and 2.35 (95 percent CI, 1.20 to 4.61), respectively. There were no statistically significantly correlations for men or participants aged younger than 80 years. The patterns were similar for at-fault MVCs.

"Practitioners should consider behavioral treatment before initiating low doses of zolpidem and escalating it as needed to achieve restorative sleep in females and individuals aged ≥80 years to reduce the risk of zolpidem-associated MVCs," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »